Comparison Of Sokal, Hasford And Eutos Scores In Terms Of Long-Term Treatment Outcome According To The Risks In Each Prognostic Model: A Single Center Data Analyzed In 255 Early Chronic Phase Chronic Myeloid Leukemia Patients Treated With Frontline Imatinib Mesylate.